4 New endocrine approaches to breast cancer

This publication has 64 references indexed in Scilit:

• Endocrine and Antitumor Effects of Combined Treatment with an Antiprogestin and Antiestrogen or Luteinizing Hormone-Releasing Hormone Agonist in Female Rats Bearing Mammary Tumors*
  Endocrinology, 1989
• GROWTH STIMULATION OF T47D HUMAN BREAST CANCER CELLS BY THE ANTI- PROGESTIN RU486
  Endocrinology, 1989
• Tamoxifen Withdrawal Response
  Archives of internal medicine (1960), 1989
• Regulation of epithelial cell proliferation by transforming growth factors
  Journal of Cellular Biochemistry, 1989
• Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trial
  European Journal of Cancer and Clinical Oncology, 1988
• Expression of Transforming Growth Factor α and its Messenger Ribonucleic Acid in Human Breast Cancer: Its Regulation by Estrogen and its Possible Functional Significance
  Molecular Endocrinology, 1988
• Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors
  Critical Reviews in Oncology/Hematology, 1986
• A New Hormonal Therapy for Prostatic Cancer: Long‐term Clinical and Hormonal Response
  British Journal of Urology, 1986
• RU486, A Progestin and Glucocorticoid Antagonist, Inhibits the Growth of Breast Cancer Cells via the Progesterone Receptor*
  Journal of Clinical Endocrinology & Metabolism, 1985
• ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1
  The Lancet, 1896